DOCSLIB.ORG

BOOKLET Santiago

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BOOKLET Santiago !1 14th International Symposium on Variants in the Genome: detection, sequencing & interpretation 5 - 7 June 2017 NH Collection Santiago Santiago de Compostela, Spain Scientific Programme Committee Prof. Johan T. den Dunnen (Leiden, Nederland) CHAIR Prof. Sir John Burn (Newcastle, UK) Prof. Angel Carracedo (Santiago de Compostela, Spain) Dr Reece Hart (San Francisco, CA, USA) Dr Andreas Laner (Munich, Germany) Dr Maria-Jesus Sobrido (Santiago de Compostela, Spain) Organising Committee Maria Torres (CEGEN-PRB2, Universidade de Santiago de Compostela) Rania Horaitis; Event Manager (Meeting Makers www.meeting-makers.com) Previous Meetings 2003 Palm Cove, Australia 1991 Oxford, UK 2005 Santorini, Greece 1993 Lago D’Orta, Italy 2007 Xiamen, China 1995 Visby, Sweden 2009 Paphos, Cyprus 1997 Brno, Czech Republic 2011 Santorini, Greece 1999 Vicoforte, Italy 2013 Lake Louise, Canada 2001 Bled, Slovenia 2015 Leiden, Netherlands !2 !3 !4 !5 !6 !7 !8 !9 !10 !11 !12 !13 Oral Presentation Abstracts Exomiser to include an assessment of SESSION 1 regulatory regions, in an application called the Genomiser. Simulations show an ability to rank the seeded causative variant in first place Phenotype Driven Genomic over an entire genome in over 60% of cases. Diagnostics In this talk, I will review how computational phenotype analysis with the HPO works and Peter N Robinson how we have used it for the Exomiser and Genomiser. Professor of Computational Biology, The Jackson Laboratory for Genomic Medicine, 10 Discovery Drive, Farmington, CT 06032, USA CNV detection from targeted peter.robinson@jax.org next-generation panel sequencing www.jax.org Robinson lab: https://robinsongroup.github.io/ data in routine diagnostics Anna Benet-Pagès, Anke M. Nissen, Janine The analysis of phenotype plays a key role in Graf, Christina Rapp, Melanie Locher, Andreas clinical practice and medical research but is Laner, Elke Holinski- Feder. difficult to compute“ on. The Human Phenotype Ontology (HPO) provides a Medizinisch Genetisches Zentrum, MGZ, standardized, controlled vocabulary that Munich, Germany allows phenotypic information to be described in an unambiguous fashion and has been Gene dosage abnormalities account for a adopted by a number of groups including the significant proportion of pathogenic mutations NIH Undiagnosed Diseases Program (UDP) in rare genetic disease related genes. In times and the UK 100,000 Genomes Project. The of next generation sequencing (NGS), a single HPO makes clinical data “computable”, and analysis approach to detect SNVs and CNVs allow a shift from binary phenotype analysis from the same data source would be of great (patient cohort vs. control) to an analysis of benefit for routine diagnostics. However, CNV phenotypic profiles that offers a foundation for detection from exon-capture NGS data has no computational approaches to integrating standard methods or quality measures so far. clinical data in precision medicine. HPO- Current bioinformatics tools depend solely on based algorithms integrate phenotype read depth which is systematically biased. We specificity, imprecision, noise and frequency developed a novel approach based on: 1. to identify matching diseases and patients. utilization of five independent detection tools We have developed Exomiser to identify to increase sensitivity, 2. different reference promising candidate genes in whole exome sets for different kits and normalization sequencing WES studies by ranking candidate against samples from the same sequencing genes according to phenotypic similarity to run to improve robustness against workflow human, mouse, and zebrafish mutant conditions, 3. definition of special quality phenotypes. Using simulated exomes and the thresholds for single exon events to minimize NIH UDP patient cohort showed Exomiser false negatives, 4. identification of reliable ranked the causal variant as the top hit in 97% regions by assessment of capture efficiency of known disease–gene associations. We have using a reference set of CNV negative patients developed a machine learning algorithm that to minimize false positives. A CNV is called in provides a pathogenicity score for each base a reliable region if at least two out of five tools of the non-coding genome, and extended the are concordant for the respective CNV. The !14 pipeline shows a sensitivity of 80% and a challenges to variant disease interpretation. A precision of 95%. Within routine gene panel typical WGS of an individual identifies diagnostics we analyzed a total of 1088 ~5million non-reference variants, a 50 fold patients indicated to have rare Mendelian increase compared to whole exome diseases for SNV and CNVs. In 32 patients a sequencing (WES). A considerable proportion CNV was detected in genes associated with of this “variant avalanche” (10-15%) resides the respective individual phenotype. within transcription regulatory elements - Interestingly, in several cases the CNV promoters and enhancers. Promoters are completed the patients report as it was relatively easy to identify due to their detected in genes with a recessive mode of stereotyped positioning at the immediate 5’ inheritance where previously only a neighborhood of genes, and their targets are heterozygous pathogenic SNV was found. quite obvious. In contrast, the identification of Overall, with the additional analysis of CNVs enhancers constitutes a major challenge. An we increased the diagnostic yield from 15% equally difficult task is identifying the (class 4, 5 single nucleotide events) to 18%. connections between these distant-acting However, there are still issues in the detection regulatory elements and their target genes. of CNVs from NGS data for routine Genomic enhancers are centrally involved in diagnostics. CNV pipelines are very prone to the spatiotemporal orchestration of gene errors caused by enrichment inconsistencies expression in embryonic development and in compared to SNV detection tools. The cell differentiation. This makes them prime assessment of sensitivity and specificity is novel targets for annotating the plethora of difficult due to the lack of datasets to validate non-coding variants in WGS, and interpreting CNV detection pipelines. Originally, the them in the realms of health and diseases. analysis of CNVs was performed mainly in Methodology: We created GeneHancer, a patients with mental retardation disorders, novel regulatory element database, in the resulting in a paucity of CNV data linked to framework of the GeneCards suite other Mendelian diseases. Moreover, the (www.genecards.org). We integrated four identification of the actual size and thus the enhancer data sources: a) 176,000 enhancer assessment of pathogenicity of a CNV is regions from the ENCODE project (https:// difficult, because targeted NGS gene panels www.encodeproject.org/); b) 213,000 do not cover all genes. In conclusion, NGS elements from the Ensembl regulatory build data is a suitable data source for the (http://www.ensembl.org/index.html); c) simultaneous detection of SNVs and CNVs for 43,000 elements from FANTOM (http:// clinical diagnosis; however, with the current fantom.gsc.riken.jp/), identified via enhancer tools it is only applicable in accurately RNAs (eRNAs); d) 1,700 experimentally- validated regions. validated elements from the VISTA enhancer browser (http://enhancer.lbl.gov/). Subsequently, we consolidated gene- GeneHancer and VarElect: enhancer links obtained by five disease interpretation of whole methodologies: a) GTEx expression genome sequence variants quantitative trait loci (eQTLs, http:// www.gtexportal.org/home/), b) Capture Hi-C Simon Fishilevich, Naomi Rosen, Michal Twik, promoter-enhancer long range interactions Rotem Hadar, Tsippi Iny-Stein, Marilyn Safran (PMID 25938943); c) FANTOM expression and Doron Lancet correlations between eRNAs and candidate target genes; d) Expression correlations Department of Molecular Genetics, Weizmann between enhancer-targeted transcription Institute of Science, Rehovot 7610001, Israel factors and genes; e) Enhancer-gene genomic Purpose: The emergence of whole genome distance scores. sequencing (WGS) poses considerable !15 Results: GeneHancer portrays 285,000 ChromiumTM: Full spectrum integrated non-redundant candidate genome analysis with Linked- enhancers (covering 12.4% of the genome), along with annotation-derived confidence Reads scores. In parallel, our database incorporates Steve Glavas, Sarah Garcia, Claudia ~1.02 million integrated and scored gene- Catalanotti, Haynes Heaton, Patrick Marks, enhancer links involving 101,337 genes. Michael Schnall-Levin, Stephen Williams, Among these, we define a subset of “double Andrew Wei Xu, Grace Zheng, Deanna M. elite” enhancer-gene pairs, based on the Church conjunction of two or more methods for both entities. This allows WGS variants within enhancers to be interpreted with high 10x genomics, Inc. confidence, based on high-probability target gene links. These WGS analysis capabilities High-throughput sequencing has are being embedded within the GeneCards revolutionized genome analysis. However, it is Suite, among others by modifying VarElect clear that traditional short read methods and TGex, its next generation sequencing provide an incomplete view of the genome (NGS) disease interpretation tools [PMID: and result in an incomplete understanding of 27357693]. the clinical and biological complexity present. For WES, VarElect prioritizes a list of variant- In particular, the lack of long-range containing genes by seeking the relevance of information combined with inherent limitations such
Load more

Recommended publications
  • 5 EVENTS in ONE: Head Real World Evidence and Big Data Solutions Novartis, Switzerland
    FIFTH ANNUAL - LIFE SCIENCE R&D DATA INTELLIGENCE LEADERS FORUM Basel, Switzerland January 23-24th, 2018 Optional Workshop 22nd, January Hear keynote presentations from the experts: Etzard Stolte Global Head Knowledge Management Roche, Switzerland Abhimanyu Verma 5 EVENTS IN ONE: Head Real World Evidence and Big Data Solutions Novartis, Switzerland Day 1: Torsten Niederdraenk Head of Technology Center Strategic Developments in R&D Big Siemens Healthcare, Germany Data Catherine Brownstein Scientific Director Day 2 (am): Stream 1 Manton Center for Orphan Disease Research Boston Children’s Hospital, USA Discovery & Omics Data Excellence Navin Ramachandran Radiology Consultant Day 2 (am): Stream 2 University College London Hospitals NHS Foundation Trust, Healthcare specialist in distributed ledgers and IoT Clinical & Patient Level Data IOTA Foundation, UK Excellence Marie-Claire Peakman Executive Director, Head Hit Discovery & Lead Profiling, Medicine Design Day 2 (pm): Stream A Pfizer, USA R&D IT & Bioinformatics Alex Zhavoronkov Co-founder, Insilico Medicine, CSO Day 2 (pm): Stream B The Biogerontology Research Foundation, UK Ivana Schnur Digital Health Collaborations Co-founder, CMO Sense.ly, USA Pre-Event Workshop: Jan 22nd Paul Wicks Artificial Intelligence for Drug Vice President of Innovation PatientsLikeMe, UK Discovery: Workshop for Senior Jazz Panchoo Global Strategy Head, VP, Digital Platforms Executives Ascensia Diabetes Care, Switzerland This Event is Certified for Continuing Professional Development with more than 30 presentations
    [Show full text]
  • Swiss Biotech Report – "Agility, Leadership and Innovation in the Time of COVID-19” – Is Indeed Appropriate
    SwissSwiss BiotechBiotech ReportReport 2021 2019Agility, leadership and innovation in the time of COVID-19 Schweizerische Eidgenossenschaft Confédération suisse Confederazione Svizzera Confederaziun svizra Swiss Confederation Innosuisse – Swiss Innovation Agency “The biopharma industry’s response to COVID-19 has truly been a global one – with Swiss companies and academic institutions at the forefront. Swiss-based biopharma players are contributing across the spectrum of patient needs.” George Scangos | Vir Biotechnology, Inc. “2020 was the best year ever for Swiss biotech in relation to financing activities, with a total of approximately CHF 3.4B raised” Jürg Zürcher | GSA Biotechnology Leader, EY “Compared to 2019, trading volumes rose sharply by 177% and the total free float market capitalization of all SIX-listed biotech companies was up 30% on 2020.” Fabian Gerber | SIX Agility, leadership and innovation in the time of COVID-19 “Technologies developed by scientists in Switzerland have been crucial in the fight against COVID-19, including cloning the virus, cryo electron microscopy to visualize the spike proteins, and the use of radioactive molecules that bind to receptor proteins to investigate how the virus enters the host.” Florian Fisch | Swiss National Science Foundation “On May 1 2020, Moderna and Lonza announced a strategic collaboration to enable manufacturing of up to 1 billion doses of the vaccine per year. Lonza acquired equipment and built the production lines in just 8 months.” Jan Lucht | scienceindustries “Industrial
    [Show full text]
  • European Human Genetics Conference 2017 Programme
    There’s nothing more 1967 - 2017 | 50th Anniversary Meeting personal than genomics Discover genomic solutions across the research continuum Visit us at stand 140 and discover how our portfolio of next-generation sequencing (NGS), microarray and informatic solutions can help empower your next breakthrough. EUROPEAN HUMAN Come learn how you can become a part of the scientic innovation happening in: GENETICS CONFERENCE 2017 • Complex Diseases • Rare or Undiagnosed Genetic Diseases Bella Center | Copenhagen, Denmark | May 27 - 30 • Reproductive Health • Cancer Genetics • Microbiology Experience the NovaSeq™ Series Discover a leap forward in technology by attending one of our stand presentations, or take a virtual reality tour. Attend the Illumina Satellite Workshop Sunday, 28 May | 19.15 – 20.45 | Room Ballerup Anniversary Meeting | Programme | European Human Genetics Conference 2017 | Copenhagen - Denmark 2017 | Copenhagen Human Genetics Conference | European Anniversary Meeting | Programme th 1967 - 2017 | 50 www.illumina.com Programme For Research Use Only. Not for use in diagnostic procedures. © 2017 Illumina, Inc. All rights reserved. European Society www.eshg.org @eshgsociety of Human Genetics facebook.com/eshg.org #eshg2017 GENERAL FLOORPLAN METRO Ground Floor Ballerup LECTURE HALLS B - CORPORATE SATELLITES Berlin Barcelona Brussels Birmingham Belgrade WC WC WC WC Bags Registration CENTERHALL Exhibition Service WC Athens Lead Retrieval Poster Printing LECTURE HALLS A Cambridge Gastro Café Exhibition Aarhus Centre Coffee & Lunch Preview Copenhagen Cash Bar MAIN LOBBY Live Stream Posters Amsterdam E-Posters WC AC Hotel FOYER Bella Sky LECTURE HALLS C Cannes Main Entrance Cologne First Floor 5 Athens CENTERHALL 16 17 WC 18 25 A Aarhus 18 19 20 LECTURE HALLS A Amsterdam MAIN LOBBY FOYER Ancona conf.
    [Show full text]
  • Sophia GENETICS SA (Exact Name of Registrant As Specified in Its Charter)
    As filed with the Securities and Exchange Commission on July 23, 2021 Registration No. 333-__________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) Switzerland Not Applicable (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Rue du Centre 172, CH-1025 Saint-Sulpice, Switzerland (Address of Principal Executive Offices) SOPHiA GENETICS Incentive Stock Option Plan SOPHiA GENETICS 2019 Incentive Stock Option Plan (Full title of the plans) SOPHiA GENETICS, Inc. 185 Dartmouth Street, Suite 502 Boston, MA 02116 (Name and Address of Agent For Service) (617) 982-1210 (Telephone number, Including Area Code, of Agent For Service) Copies of all communications, including all communications sent to the agent for service, should be sent to: Kyoko Takahashi Lin Davis Polk & Wardwell LLP 450 Lexington Avenue New York, NY 10017 (212) 450-4000 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer o Accelerated filer o Non-accelerated filer o Smaller reporting company o (Do not check if a smaller reporting company) Emerging Growth Company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
    [Show full text]
  • ESMO 2019 Exhibitors' List
    ESMO 2019 - Exhibitors' list (as of 21 of August 2019) Booth Number Company name 441 3D TECH OMEGA ZETA 469 3DforScience - Visuals for Bio & Health 235 10x Genomics 315 AbbVie 227 Abcam 213 Accord Healthcare 471 Adaptive Biotechnologies 208 Advanced Accelerator Applications, a Novartis company 465 Agendia 456 Alkermes, Inc 473 Almac Group 403 Amgen Inc. 415 Amoy Diagnostics Co., Ltd. 211 Aptitude Health 248 ArcherDX 309 Astellas 305 AstraZeneca 467 Avaden BioSciences, Inc. 463 Axiom Healthcare Strategies 446 Baxter 306 Bayer 419 BEACON Medicare Limited 443 BEIGENE, LTD. 233 Biocartis 245 Biotype GmbH 302 Bristol-Myers Squibb 401 Boehringer Ingelheim 238 Calithera Biosciences 476 Cancer Drug Interactions 407 Caris Life Sciences 225 CATALYSIS S.L. 318 CeGaT 215 Celgene 409 Celltrion Healthcare Co., Ltd. 454 Chemo Mouthpiece 450 Clinical Research Malaysia 217 Clovis Oncology 421 COMECER 411 Covance, Inc. 462 Cytel 205 Daiichi Sankyo, Inc. 413 DAVA Oncology 452 ECS Progastrin 207 Eisai Ltd. 229 Elevar 239 EntroGen 247 Erytech Pharma SA 440 Europital 402 EUSA Pharma 214 Exelixis, Inc. 303 F. Hoffmann-La Roche AG 458 Ferring Pharmaceuticals 244 FibroGen, Inc. 455 FRENCH HEALTHCARE 422 Fresenius Kabi 448 geneXplain GmbH 221 Genmab 404 GENOMIC HEALTH 206 GSK 249 Guardant Health 246 HalioDx 474 Halozyme Therapeutics 417 Helsinn Healthcare 445 HTG Molecular Diagnostics 251 IBM Watson Health 319 Illumina 477 ImaginAb, Inc. 216 Incyte Biosciences International Sàrl 242 Institut Curie 310 IPSEN 472 IQVIA Biotech 210 ITM Isotopen Technologien Muenchen AG 220 Janssen-Cilag International NV P432 Jiahui International Hospital 406 Kaiku Health 420 Kite, a Gilead Company 236 KoNECT (Korea National Enterprise for Clinical Trials) 475 Leica Biosystems 307 Lilly 237 Linical 204 Loxo Oncology, Inc.
    [Show full text]
  • Cynosure Aces Single-Audit Program Twice
    POLICY & REGULATION COMMERCIAL R&D An update on NEST real-world Mark Hitchman of Canon Medical Two firms nab US breakthrough evidence efforts, p. 6 Systems discusses market growth status, p. 22 strategies, p. 15 Medtech Issue 80 Pharma Intelligence Informa February 5, 2018 medtech.pharmaintelligence.informa.comInsight 'WE SURVIVED MDSAP': The final visit from the US agency that year was the last straw, she said. "That FDA inspection really made me Cynosure Aces Single-Audit Program want to get Cynosure involved in MDSAP because I cancelled a vacation to Indonesia Twice; Tells How Your Firm Can, Too to stay behind for that inspection," Hoy said. "That's when I learned that travel insurance SHAWN M. SCHMITT shawn.schmitt@informa.com doesn't consider an FDA inspection to be an emergency that's reimbursable." MDSAP , created by the International Medical Device Regulators Forum (IMDRF), allows firms to undergo only one audit by an accredited third party to satisfy quality regulations for five countries: the US, Can- ada, Brazil, Japan and Australia. The program runs on a three-year cycle, albeit with differing scopes for each audit. Firms are certified to MDSAP in the first year; in the second and third years, they submit to surveillance audits, which are typically quicker than a certification audit. The cycle then repeats, with recertification to MDSAP Shutterstock: alphaspirit Shutterstock: occurring in the fourth year, and so on. MDSAP ran as a pilot program for three or longtime quality and regulatory "It was particularly difficult that year to full years from January 2014 through expert Connie Hoy, the decision to be in the quality department at Cynosure December 2016, but is now a bona-fide F ditch the prying eyes of multiple because all we did was get audited.
    [Show full text]
  • People Recent Moves of Note in and Around the Biotech and Pharma Industries
    careers & recruitment People Recent moves of note in and around the biotech and pharma industries. held various leadership roles at Novartis, Turning Point Therapeutics has announced the appointment including development franchise head of of Siegfried Reich (photo) as executive vice president respiratory, development franchise head of and CSO. Reich has over 25 years of pharma and biotech primary care, and global head of clinical experience developing more than 20 drug candidates. He was operations, analytics and regions. most recently senior vice president of research and cofounder of eFFECTOR Therapeutics, and before that was vice Michael Quigley has joined Gilead Sciences president and head of drug discovery at SGX, vice president as senior vice president, research biology. and head of viral and ophthalmic diseases at Pfizer, and He was most recently vice president and director and head of medicinal chemistry at Agouron. head of Bristol-Myers Squibb’s thematic “With a strong commitment to build on the four internally discovered drug research center for tumor microenvironment candidates in our pipeline, we wanted to attract a proven leader and visionary CSO modulation and site head of its Redwood to advance our research strategy,” said Athena Countouriotis, president and CEO of City, California location. Turning Point. “Siegfried is an ideal fit for our team, with deep discovery and novel- target-identification expertise, and a proven track record of developing drug candidates Verana Health has appointed Matthew Roe for difficult-to-drug targets through disciplined discovery and medicinal, structure- and chief medical officer. Roe is a cardiologist fragment-based chemistry.” and clinical researcher who has spent over two decades at the Duke University School of Medicine and the Duke Clinical Research Robert Abraham has been named CSO Therapeutics.
    [Show full text]
  • Sophia GENETICS SA Ordinary Shares This Is an Initial Public Offering of Ordinary Shares by Sophia GENETICS SA
    Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-257646 Prospectus 13,000,000 Shares SOPHiA GENETICS SA Ordinary Shares This is an initial public offering of ordinary shares by SOPHiA GENETICS SA. We are offering 13,000,000 ordinary shares. The initial public offering price is $18.00 per ordinary share. Prior to this offering, there has been no public market for our ordinary shares. Our ordinary shares have been approved for listing on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “SOPH.” Instrumentarium Holdings, Inc., an affiliate of GE Precision Healthcare LLC (“GE Healthcare”), has agreed to purchase $20.0 million of our ordinary shares in a private placement concurrent with and contingent upon the completion of this offering, with the price per share to be equal to the initial public offering price in this offering. The sale of such ordinary shares will not be registered under the Securities Act of 1933, as amended (the “Securities Act”). The closing of this offering is not contingent upon the closing of such concurrent private placement. We will not pay any underwriting discounts or commissions for the ordinary shares sold in the concurrent private placement. See “Prospectus Summary—Recent Developments—Private Placement.” We are an “emerging growth company” as defined under U.S. federal securities laws and, as such, may elect to comply with reduced public company reporting requirements for this and future filings. See “Prospectus Summary—Implications of Being an Emerging Growth Company.” Per Share Total Initial public offering price $ 18.00 $234,000,000 Underwriting discounts and commissions(1) $ 1.26 $ 16,380,000 Proceeds to SOPHiA GENETICS SA, before expenses $ 16.74 $217,620,000 (1) See “Underwriting” for a description of all compensation payable to the underwriters.
    [Show full text]
  • Swiss Biotech Report 2020
    Swiss Biotech Report 2020 Jürg Zürcher and Michael Altorfer April 21, 2020 Swiss biotech hub: A tight cross-functional network Veterinary R&D CMO Bio-IT Analytical Therapeutics Engineering Swiss Biotech Cell culture Hub Food & industrial Medtech Biotech consulting Diagnostics Agriculture Chemicals reagents Labware Bio-equipment Non-biotech consulting April 21, 2020 3 Swiss Biotech Report 2020: Continued sector growth • Biotech industry generates revenues of CHF 4.8 billion in 2019, up from CHF 4.0 billion in 2018 • Over CHF 1 billion raised for private and public companies • Licensing deals and collaborations boost revenues • Gene therapy, AI and advanced biologics manufacturing emerging as additional strengths • Over 40 new start ups set up in 2019 April 21, 2020 4 Life sciences account for 40% of Swiss exports Pharma and biotech together CHF 97.5 bn in 2019 April 21, 2020 5 Emerging new strengths Manufacturing of complex biologicals and exploitation of AI • Biogen, CSL Behring, Novartis and Merck invest heavily in expanding production capacity • Increasing number of complex biologicals and cell therapies gain approval • AI being exploited by companies such as SOPHiA GENETICS, BC Platforms, Genedata, Insphero, GenomSys and SimplicityBIO April 21, 2020 6 Artificial intelligence: Emerging business opportunities Interviews with Jurgi Camblong, SOPHiA GENETICS and Axel Nemetz, IBM • AI applications offer new business opportunities in healthcare • SOPHiA GENETICS and IBM represent two complementary examples • Both develop globally applicable
    [Show full text]
  • Switzerland's Biotech
    Switzerland’s biotech hub - a powerful source of innovation AFSSI Connexions, Convention 2019, July 2nd, Lyon Michael Altorfer CEO, Swiss Biotech Association The Swiss biotech industry is a key asset Switzerland is one of the best Local companies hold and most innovative locations leading positions throughout many for biotechnology in Europe and sectors and thus attract capital and the world researchers from all over the world The basis for this success is a In addition to being an attractive close-knit network between place to live for international research and development, driven specialists, Switzerland also offers a by renowned universities, highly modern infrastructure, a specialized SMEs and strong beneficial funding environment multinational corporations and access to a highly-qualified workforce 2 swissbiotech.org A tight cross-functional network Veterinary R&D CMO Bio-IT Analytical Therapeutics Engineering SBA member company activities Cell culture Food & industrial Medtech Biotech consulting Diagnostics Agriculture Chemicals reagents Labware Bio-equipment Non-biotech consulting 3 swissbiotech.org Swiss Biotech: Structural changes offer new investment and partnering opportunities CRO share research risk Biotech companies stay independent: CMOs take over production sites • build their commercial Clinical trials are outsourced organizations and even financed by partners • partner with distributors team up with partners Service providers start that have access to SBA member sharing risks and benefit patients company activities • combine drug and Business models not relying medical device or on product development service provider Investors go it alone, build Some Biotech companies are virtual project teams rather fully financed, eliminating the than companies need for small incremental financing rounds 4 swissbiotech.org Capital investment in Swiss biotech companies 5 Swiss Biotech Day 2019 From 2007 - 2018 Venture Kick invested CHF 3.16 million in 48 Swiss biotech startups.
    [Show full text]
  • 25 to 26 September 2019 Heidelberg | Germany European Business
    Programme © Matthias Bach European Business Development Conference 25 to 26 September 2019 Heidelberg | Germany Local Hosts: Gold Sponsorships: Silver Sponsorship: Conference Supporters: Wednesday, 25 September Thursday, 26 September MORNING PROGRAMME: STARTING 10.00 AM Partnering / Breakfast: Starting 08.00 AM Opening Remarks Rainer Wessel, Director Innovation Management, DKFZ MORNING PROGRAMME: STARTING 09.00 AM Keynote Oncology Keynote Digitization / AI in Health Care Joern-Peter Halle, SVP, Head of TIP Immuno Oncology and Lorenz Mayr, Chief Technology Officer, GE Healthcare Head of External Innovation, Merck Company Presentations Company Presentations Chair: Ruth Herzog, Head of Technology Transfer, DKFZ Chair: Uwe Hanenberg, Director Product Development and • Molecular Health Director S&T, Catalent Pharma Solutions • CEVEC Pharmaceuticals • YUMAB • ALBEGA Medical • PEPperPRINT • MI-mAbs • Proteona • Immunic Session 3 • Phenex Pharmaceuticals Drug Development 4.0 – How Digitization and AI Change Drug Development Chair: Károly Földesi, Director Digital Business for Life Partnering / Lunch Sciences Germany, SAP Deutschland SE & Co. KG Confirmed Speakers: AFTERNOON PROGRAMME: STARTING 14.15 PM • Esteban Czwan, SVP Clinical Trials Business Area, Sophia Genetics Session 1 • David Harel, Chief Executive Officer, CytoReason Fighting Malignancies – Focus on Cancer Therapy • Edith Schallmeiner, Commercial Director, Customer Chair: Ulrich Zügel, Director External Science & Innovation Success EMEA-LATAM, Diagnostics Information Germany, Pfizer
    [Show full text]
  • Code of Business Conduct
    Code of Business Conduct 2021 March 2021 Code of Business Conduct 2021 Table of Content Foreword by Jurgi Camblong, Co-founder and CEO 3 Message from the Executive Team 4 Our Ethical Principles 5 Our Ethical Safeguards 6 Our Code of Business Conduct 6 Reporting of Any Illegal or Unethical Behavior 6 Our Ethics Committee 6 Reporting to a Government Agency 6 Our Commitment to our Stakeholders 7 Our Employees, Contractors and Board Members 7 The Patients of our Customers 8 Our Shareholders 9 Our Business Partners and Competitors 9 Our Community 10 © SOPHiA GENETICS 2021 2 Code of Business Conduct 2021 Foreword by Jurgi Camblong, Co-founder and CEO When founding the company with Pierre and Lars, in 2011, our goal was to create a tech company whose impact would significantly improve pa- tient care. We believe our corporate DNA, rooted in quality, precision and robustness, is the key to our success and a promise of hope for millions around the world. We’re also convinced that the success of SOPHiA GENETICS depends di- rectly on the behavior of each and every one of us. Placing ethics at the heart of our business conduct is critical to pursue our mission to build a more sustainable global healthcare system. Of course, this requires complying with all applicable laws and regula- tions, but we must go further and ensure that our business decisions are guided by a true sense of integrity. Our Code of Business Conduct was created in this spirit and sets out the ethical guidelines under which we conduct our day-to-day actions.
    [Show full text]